False-positive [ 68 Ga]Ga-FAPI-04 PET/CT Following Treatment of 177 Lu-DOTATATE PRRT in a Patient With Metastatic High-grade Well-differentiated Neuroendocrine Tumor.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41283784.
- Also identified by DOI 10.1097/RLU.0000000000006181.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We present a high-grade well-differentiated NET with large lesions that demonstrated both SSTR and [ 18 F]F-FDG avidity on baseline PET/CT, an outstanding response following 177 Lu-DOTATATE-PRRT with complete resolution of SSTR and [ 18 F]F-FDG uptake, and significant size reduction of liver lesions. Non-SSTR and non-[ 18 F]F-FDG-avid change was noted in segment V, demonstrated uptake on [ 68 Ga]Ga-FAPI-04 PET/CT, and confirmed as fibrotic changes post-PRRT. Following PRRT, analysis of [ 68 Ga]Ga-FAPI-04 PET/CT in well-differentiated NET is important to avoid misinterpretation. Benign fibrosis following treatment may show FAPI uptake as a possible source of false-positive findings on [ 68 Ga]Ga-FAPI-04 PET/CT in the evaluation of NET.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Organometallic Compounds
- Neuroendocrine Tumors
- Octreotide